Dr. Jingyao Chen focuses her practice on U.S. and foreign patent preparation and prosecution in the field of life sciences, concentrating on cell therapy, gene therapy, antibody, biologics, cell-free disease diagnostics, and microRNA innovations. She is trained in the areas of biotechnology and synthetic biology.
Prior to joining McCarter, Jingyao earned her PhD in Biomedical Engineering from Boston University. Her research primarily focused on the development of advanced cutting-edge cancer immunotherapies, tumor-targeting antibodies, CRISPR-Cas13 systems, and cell-free genetic circuits. Specifically, her work on CAR-T cell therapies led to innovative designs that enhance sensitivity, safety, and efficacy. Jingyao is also an expert in designing and characterizing cell-based and cell-free genetic circuits for environmental sensing and disease diagnostics.
Jingyao has presented her research at several prestigious conferences, including the Gordon Research Conference in Synthetic Biology, the Biomedical Engineering Society, and the AIChE Cell-Free Systems Conference.